Shares of Colfax Co. (NYSE:CFX) have been assigned a consensus rating of “Buy” from the fourteen brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $40.58.
Several equities research analysts recently issued reports on CFX shares. Deutsche Bank Aktiengesellschaft raised their target price on shares of Colfax from $53.00 to $54.00 and gave the company a “hold” rating in a research note on Friday, March 12th. Morgan Stanley raised their target price on shares of Colfax from $45.00 to $47.00 and gave the company an “equal weight” rating in a research note on Friday. Citigroup raised their target price on shares of Colfax from $35.00 to $41.00 in a research note on Monday, February 22nd. TheStreet upgraded shares of Colfax from a “c” rating to a “b-” rating in a research note on Monday, February 22nd. Finally, KeyCorp raised their price objective on shares of Colfax from $47.00 to $57.00 and gave the stock an “overweight” rating in a research report on Thursday, March 18th.
Shares of Colfax stock traded down $0.67 during trading hours on Thursday, reaching $42.99. 1,899,109 shares of the company’s stock were exchanged, compared to its average volume of 1,432,941. The company has a 50 day moving average of $44.85 and a two-hundred day moving average of $39.66. Colfax has a fifty-two week low of $22.35 and a fifty-two week high of $50.26. The company has a current ratio of 1.64, a quick ratio of 0.96 and a debt-to-equity ratio of 0.63. The stock has a market cap of $5.83 billion, a P/E ratio of -855.40, a P/E/G ratio of 2.61 and a beta of 2.15.
In other news, EVP Shyam Kambeyanda sold 1,850 shares of the firm’s stock in a transaction that occurred on Thursday, February 25th. The shares were sold at an average price of $46.01, for a total transaction of $85,118.50. Following the transaction, the executive vice president now directly owns 62,389 shares of the company’s stock, valued at $2,870,517.89. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Matthew L. Trerotola sold 6,057 shares of the firm’s stock in a transaction that occurred on Thursday, February 25th. The stock was sold at an average price of $46.01, for a total transaction of $278,682.57. Following the transaction, the chief executive officer now directly owns 233,699 shares in the company, valued at $10,752,490.99. The disclosure for this sale can be found here. Insiders have sold 40,524 shares of company stock worth $1,886,484 over the last ninety days. Insiders own 12.00% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Cooke & Bieler LP increased its holdings in shares of Colfax by 2.5% during the fourth quarter. Cooke & Bieler LP now owns 6,337,233 shares of the industrial products company’s stock worth $242,336,000 after purchasing an additional 154,193 shares during the period. Royce & Associates LP increased its stake in Colfax by 0.4% in the fourth quarter. Royce & Associates LP now owns 2,685,331 shares of the industrial products company’s stock valued at $102,687,000 after acquiring an additional 11,652 shares during the last quarter. Eaton Vance Management bought a new position in Colfax in the fourth quarter valued at approximately $4,606,000. Walleye Capital LLC bought a new position in Colfax in the fourth quarter valued at approximately $2,614,000. Finally, Tudor Investment Corp Et Al increased its stake in Colfax by 452.8% in the fourth quarter. Tudor Investment Corp Et Al now owns 160,615 shares of the industrial products company’s stock valued at $6,142,000 after acquiring an additional 131,558 shares during the last quarter. 99.56% of the stock is currently owned by institutional investors.
Colfax Corporation operates as a diversified technology company worldwide. The company operates in two segments, Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures, and supplies consumable products and equipment, including cutting, joining, and automated welding products, as well as gas control equipment.
Read More: What does a hold rating mean?
Receive News & Ratings for Colfax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colfax and related companies with MarketBeat.com's FREE daily email newsletter.